Interference from heterophilic antibodies in amyloid-β oligomer ELISAs

Journal of Alzheimer's Disease

Volumn 21, Issue 4, 2010, Pages 1295-1301

  Sehlin, Dag ^a   Söllvander, Sofia ^a   Paulie, Staffan ^b   Brundin, Rosemarie ^a   Ingelsson, Martin ^a   Lannfelt, Lars ^a   Pettersson, Frida Ekholm ^a   Englund, Hillevi ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Mabtech AB   (Sweden)

Author keywords

Amyloid ; cerebrospinal fluid; ELISA; false positive signals; heterophilic antibodies; oligomers; plasma

Indexed keywords

AMYLOID BETA PROTEIN; HETEROPHILE ANTIBODY; OLIGOMER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION;

EID: 78650484413     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100609     Document Type: Article

References (21)

1. Sian AK, Frears ER, El-Agnaf OM, Patel BP, Manca MF, Siligardi G, Hussain R, Austen BM (2000) Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem J 349, 299-308.
2. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE (2007) Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 103, 334-345.
3. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring b-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199.
4. Prince AM, Brotman B, Jass D, Ikram H (1973) Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet 1, 1346-1350.
5. Hunter WM, Budd PS (1980) Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays. Lancet 2, 1136.
6. Datta P (2008) Interference ofheterophilic and other antibodies in measurement of therapeutic drugs by immunoassays In Handbook of Drug Monitoring Methods, Dasgupta A, ed. Humana Press, Totowa, NJ, pp. 225-233.
7. Boscato LM, Stuart MC (1986) Incidence and specificity of interference in two-site immunoassays. Clin Chem 32, 14911495.
8. Zweig MH, Csako G, Benson CC, Weintraub BD, Kahn BB (1987) Interference by anti-immunoglobulin G antibodies in immunoradiometric assays of thyrotropin involving mouse monoclonal antibodies. Clin Chem 33, 840-844.
9. Thompson RJ, Jackson AP, Langlois N (1986) Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects -incidence, species specificity, and effects on atwo-site assay for creatine kinase-MB isoenzyme. Clin Chem 32, 476-481.
10. Nicholson S, Fox M, Epenetos A, Rustin G (1996) Immunoglobulin inhibiting reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Int J Biol Markers 11, 46-49.
11. Larsson A, Mellstedt H (1992) Chicken antibodies: a tool to avoid interference by human anti-mouse antibodies in ELISA after in vivo treatment with murine monoclonal antibodies. Hybridoma 11, 33-39.
12. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomark-er for Alzheimer's disease. Proc Natl Acad Sci U S A 102, 2273-2276.
13. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Bohm G (2007) Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis 11, 117-125.
14. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4, 887-893.
15. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN (2006) The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 27, 67-77.
16. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L (2006) Physiochemical characteriza-tionofthe Alzheimer's disease-related peptides Aft 1-42Arctic and Ab 1-42wt. FEBSJ 273, 2618-2630.
17. Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE (2009) Oligomeriza-tion partially explains the lowering ofAbeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis 6, 139-147.
18. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58, 147150.
19. Reiber H (1995) External quality assessment in clinical neu-rochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 41, 256263.
20. Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN (2009) Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBSJ 276, 995-1006.
21. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEBJ 20, 419-425.